NCI-MATCH Patient Eligibility

The NCI-MATCH trial includes a large number of rare and common cancer types, while most other precision medicine cancer trials address a single cancer. It is a phase II study that seeks to determine whether matching certain drugs or drug combinations in adults whose tumors have specific gene abnormalities will effectively treat their cancer, regardless of their cancer type. Such discoveries could be eligible to move on to larger, more definitive trials.

The trial is for cancer patients who meet all of the following pre-qualifications:

  • Age: adults 18 years of age and older
  • Cancer Type: any solid tumor, lymphoma (cancer in the cells of the immune system), or myeloma (cancer in the bone or soft tissue) that has returned or gotten worse after standard systemic therapy (oral or intravenous) OR a type of cancer for which no standard treatment exists that has been shown to prolong overall survival
  • Location: patients must be receiving care at a participating cancer center or community hospital in the United States. For locations, visit the NCI-MATCH Home Page.
  • Tumor Gene Testing: patients with a referral from a designated commercial or academic laboratory that shows they have a gene abnormality and disease characteristics that match one of the treatment arms in the trial

Tumor gene testing by a designated lab is the only pathway for patients to enroll in the NCI-MATCH trial

For more information, visit the Genomic Testing section.

Disclaimer: Personnel in clinical sites must review the master protocol for complete eligibility requirements and NOT rely upon this overview, which is not intended to be a comprehensive listing of inclusion and exclusion criteria.

ECOG-ACRIN Cancer Research Group